Amorphous Abiraterone Acetate Solid Dosage Form
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current abiraterone acetate formulations for treating prostate cancer exhibit low bioavailability, significant food effects, and high variability in pharmacokinetics, leading to efficacy and safety issues due to rapid conversion and variable exposure when taken with meals.
Innovation Solution
Development of a solid dosage form with a stable, amorphous matrix comprising abiraterone acetate, water-soluble polymers, and antioxidants, capable of rapid reconstitution or disintegration in the oral cavity or an aliquot of liquid, which includes specific excipients like polyvinylpyrrolidone and antioxidants to enhance bioavailability and reduce variability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If abiraterone acetate is administered as conventional immediate release tablets, then the drug can be orally administered, but the bioavailability is low and pharmacokinetics show high variability
Solution Approach 1:
The patent transforms abiraterone acetate from crystalline form to amorphous form, fundamentally changing the physical state parameter. This amorphous formulation increases solubility and bioavailability while reducing the need for complex administration instructions, as the drug no longer requires fasting conditions for consistent absorption
Solution Approach 2:
The patent creates a composite amorphous solid dispersion system combining abiraterone acetate with excipients such as hydroxypropyl cellulose and silicon dioxide. This composite material approach stabilizes the amorphous state and maintains consistent drug release profiles, improving reliability without requiring overly complex formulation processes
2Ease of operation
If abiraterone acetate is taken with meals, then patient compliance improves, but the food effect causes up to 10-fold increase in AUC and 17-fold increase in Cmax
Solution Approach 1:
By changing the physical state from crystalline to amorphous, the patent fundamentally alters the dissolution behavior of abiraterone acetate. The amorphous form maintains consistent solubility regardless of food presence, allowing patients to take the drug with meals while avoiding the extreme pharmacokinetic variability (10-fold AUC increase, 17-fold Cmax increase) associated with conventional formulations
Solution Approach 2:
The amorphous excipient matrix acts as an intermediary that buffers the interaction between the drug and food components. This matrix controls drug release and dissolution independently of the gastrointestinal environment, eliminating the harmful food effect while preserving administration convenience
3Reliability
If the dose of abiraterone acetate is increased to overcome resistance, then efficacy against CRPC xenografts improves, but safety issues arise due to variable exposure
Solution Approach 1:
The amorphous formulation provides predictable and consistent drug exposure through improved solubility and dissolution characteristics. This consistency allows for reliable dosing that achieves therapeutic efficacy against CRPC xenografts while avoiding the safety issues associated with variable exposure and unpredictable peak concentrations that occur with conventional formulations
Data Source
AI summary
Methods and compositions for treating prostate cancer are described herein. More particularly, the methods for treating prostate cancer comprise administering abiraterone acetate in the form of a solid dosage form for oral administration wherein said solid dosage form for oral administration is capable of rapid reconstitution or disintegration in the oral cavity or an aliquot of liquid prior to ingestion, suitably administered in combination with a steroid.